Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $12.3333.

EVAX has been the topic of a number of research analyst reports. Lake Street Capital increased their price objective on shares of Evaxion A/S from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a report on Monday, October 20th. Finally, Edward Jones began coverage on Evaxion A/S in a report on Thursday, October 30th. They set a “buy” rating and a $10.00 price objective on the stock.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $5.12 on Wednesday. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The stock has a market capitalization of $42.70 million, a PE ratio of -13.13 and a beta of 0.28. The stock’s fifty day moving average is $5.82 and its 200-day moving average is $3.78.

Hedge Funds Weigh In On Evaxion A/S

An institutional investor recently raised its position in Evaxion A/S stock. Merck & Co. Inc. boosted its holdings in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,214,126 shares of the company’s stock after acquiring an additional 671,847 shares during the period. Evaxion A/S accounts for 1.4% of Merck & Co. Inc.’s portfolio, making the stock its 6th largest position. Merck & Co. Inc. owned 86.54% of Evaxion A/S worth $2,246,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.